


Product Details

Summary

Catalog#	ATEP02461COV
description	Recombinant SARS-CoV-2 NSP1 is produced by E.coli expression system and the target gene encoding Met1-Gly180 is expressed with N-His Tag
Expression system	E.coli
Species	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Accession #	YP_009725297.1
Alternative names	SARS-CoV 2 nsp1, SARS-CoV 2 Leader protein
Predicted Molecular Mass	21.94kDa
Actual Molecular Mass	22-23kDa
Purity	>90% as determined by SDS-PAGE
Endotoxin level	Please contact with the lab for this information.
Formulation	Supplied as lyophilized from PBS, pH7.4, 0.02% NLS, 1mM EDTA, 4% trehalose, 1% mannitol.
Shipping	In general, proteins are shipped out with blue ice unless customers require otherwise.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week . Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution	Reconstitute in sterile water for a stock solution.
Application	Immunogen

SDS-PAGE image



SDS-PAGE Image

Background

The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ~30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses.

Product performance

Form

Recombinant 2019-nCoV NSP1

Note

For research use only.

